| Ytd | -28.13% | |
| 1y | -28.76% |
| Open | 1.61 | Prev Close | 1.69 | Low | 1.53 | High | 1.68 | Mkt Cap | 541.37M |
| Vol | 0.00 | Avg Vol | 1.16M | EPS | -0.53 | P/E | -3.04 | Forward P/E | -5.33 |
| Beta | 1.79 | Short Ratio | 3.72 | Inst. Own | 30.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 1.71 | 200-d Avg | 2.06 | 1yr Est | 5.83 |
PROK News
ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus
Stocks up, Dow Jones +100 points. AEVEX Corp shares rose 11.8% on $50m Air Force contract. Other big
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Che
ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus
WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report)
WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”
Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have earned a consensus rating of "Modera
ProKidney (NASDAQ: PROK - Get Free Report) will likely be releasing its Q4 2025 results before the m
PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA al
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have been given a consensus recommendatio
WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
WINSTON-SALEM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report
WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay
I rate ProKidney a buy due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA ali
ProKidney Corp. (NASDAQ:PROK ) Citi's Biopharma Back to School Conference September 3, 2025 10:30 AM
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after
During the session on Thursday, 461 stocks hit new 52-week lows.
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announ
Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Frida
Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Fr